Medline (NASDAQ:MDLN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Medline (NASDAQ:MDLN) have earned a consensus rating of “Moderate Buy” from the twenty-nine analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, twenty-one have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $50.8462.

MDLN has been the topic of several recent analyst reports. Evercore reissued an “outperform” rating and set a $55.00 target price on shares of Medline in a research report on Wednesday, February 25th. BNP Paribas Exane dropped their target price on shares of Medline from $49.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Medline from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Morgan Stanley lifted their target price on shares of Medline from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Finally, Citigroup dropped their target price on shares of Medline from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th.

Medline Trading Down 7.0%

Shares of NASDAQ MDLN opened at $36.19 on Friday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $50.88. The company has a 50-day simple moving average of $43.47.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion during the quarter. The company’s revenue was up 10.7% on a year-over-year basis. As a group, sell-side analysts expect that Medline will post 1.5 earnings per share for the current year.

Hedge Funds Weigh In On Medline

Hedge funds have recently modified their holdings of the company. Sound Income Strategies LLC bought a new position in shares of Medline during the 4th quarter worth approximately $25,000. Entrust Financial LLC bought a new position in shares of Medline during the 4th quarter worth approximately $26,000. NBC Securities Inc. bought a new position in shares of Medline during the 4th quarter worth approximately $28,000. Whipplewood Advisors LLC bought a new position in shares of Medline during the 1st quarter worth approximately $30,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Medline in the 4th quarter worth approximately $31,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.